Search Results - "Grapperon, A.M"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Motor-evoked potential gain is a helpful test for the detection of corticospinal tract dysfunction in amyotrophic lateral sclerosis by Duclos, Y, Grapperon, A.M, Jouve, E, Truillet, R, Zemmour, C, Verschueren, A, Pouget, J, Attarian, S

    Published in Clinical neurophysiology (01-02-2017)
    “…Highlights • Motor-evoked potential (MEP) gain is decreased in patients with amyotrophic lateral sclerosis (ALS). • MEP gain may allow the early detection of…”
    Get full text
    Journal Article
  2. 2

    Ulnar neuropathy at the elbow: Reappraisal of the wrist-upper arm latency difference between ulnar and median nerves by Di Virgilio, G., Grapperon, A.M., Fayerstein, J., Goudot, M., Nollet, S., Ochsner, F., Théaudin, M., Truffert, A., Tsouni, P., Vial, C., Wang, F.C., Pasquier, J., Tatu, L., Attarian, S., Kuntzer, T.

    Published in Clinical neurophysiology (01-02-2020)
    “…•Ulnar neuropathy at the elbow can be diagnosed by comparing ulnar to median nerve motor latency.•Ulnar-median latency difference >0.69 ms indicates ulnar…”
    Get full text
    Journal Article Web Resource
  3. 3

    Disorders of motor neurons manifested by hyperactivity by Grapperon, A.M., Attarian, S.

    Published in Revue neurologique (01-05-2017)
    “…Neuronal and/or axonal hyperactivity and hyperexcitability is an important feature of motor neuron diseases. It results clinically in cramps and…”
    Get full text
    Journal Article
  4. 4

    Toxicité neurologique complexe des inhibiteurs de check point by Muller, R., Grapperon, A.M., Kouton, L., Verschueren, A., Delmont, E., Salort-Campana, E., Attarian, S.

    Published in La revue de medecine interne (01-12-2020)
    “…Les inhibiteurs de check point (ICP) ont révolutionné la prise en charge thérapeutique de nombreux cancers. Leur mode d’action novateur consiste à réprimer…”
    Get full text
    Journal Article
  5. 5

    Un train peut en cacher plusieurs autres : myosite, myocardite et autres réactions auto-immunes fatales secondaires à un traitement par nivolumab by Le Roux, A., Grapperon, A.M., Kouton, L., Verschueren, A., Delmont, E., Salort-Campana, E., Attarian, S.

    Published in La revue de medecine interne (01-12-2019)
    “…Depuis une dizaine d’années, les immunothérapies inhibitrices des check-point blockers anti-PD1, anti-PDL1 et anti-CTLA4 complètent de manière efficace…”
    Get full text
    Journal Article
  6. 6